Your browser doesn't support javascript.
loading
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.
Park, Robin; Al-Jumayli, Mohammed; Miller, Kirk; Saeed, Azhar; Saeed, Anwaar.
Afiliação
  • Park R; MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, United States.
  • Al-Jumayli M; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, Kansas, United States.
  • Miller K; Department of Radiology, Kansas University Medical Center, Kansas City, Kansas, United States.
  • Saeed A; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, Kansas, United States.
  • Saeed A; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, Kansas, United States. Electronic address: asaeed@kumc.edu.
Cancer Treat Res Commun ; 27: 100342, 2021.
Article em En | MEDLINE | ID: mdl-33611092

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Cloridrato de Erlotinib Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Treat Res Commun Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Cloridrato de Erlotinib Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Treat Res Commun Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos